Does insurance cover Wegovy in Illinois?

Navigating insurance coverage for popular weight-loss and diabetes medications like Wegovy, Ozempic, and Mounjaro can feel like solving a puzzle with missing pieces. If you’ve been prescribed one of these GLP-1 medications—or are considering them—you’re likely facing questions about whether your insurance will pay, what hoops you’ll need to jump through, and what to do if you’re denied coverage.

The short answer: It depends—on your insurance type, your diagnosis, and where you live. In 2025, coverage for these medications remains inconsistent across commercial plans, Medicare, and Medicaid, with many patients encountering denials or strict requirements. But understanding the landscape can help you advocate for yourself and find the most affordable path forward.

Understanding GLP-1 Medications: What They Are and Why Coverage Varies

Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are all GLP-1 receptor agonists—medications that mimic a natural hormone to regulate blood sugar and appetite. While they share similar mechanisms, they’re FDA-approved for different uses:

• Ozempic and Mounjaro are approved for Type 2 diabetes management
• Wegovy is specifically approved for chronic weight management in adults with obesity or overweight with weight-related health conditions

This distinction matters enormously when it comes to insurance coverage. Diabetes medications are generally considered essential health benefits under the Affordable Care Act, while weight-loss drugs are often treated as optional—and expensive—benefits that many insurers choose to exclude.

The cost drives much of this hesitation. Without insurance or discounts, these medications typically run $900–$1,350 per month—a price tag that has prompted both insurers and state Medicaid programs to restrict or deny coverage, even as clinical evidence of their effectiveness continues to mount.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: A Patchwork of Policies

Coverage for Diabetes vs. Weight Loss

If you have commercial insurance through an employer or the ACA marketplace, your coverage story will likely differ based on why you need the medication.

For Type 2 diabetes, insurers generally cover Ozempic and Mounjaro as part of their diabetes medication formulary. However, ‘coverage’ doesn’t mean automatic approval. Most plans require:

• Prior authorization to confirm your Type 2 diabetes diagnosis
• Documentation that you’ve tried first-line treatments like metformin
• Evidence that your blood sugar isn’t adequately controlled on your current regimen

Some insurers implement step therapy, requiring you to try a less expensive GLP-1 medication before approving Mounjaro, which costs more than Ozempic.

For weight loss, the picture becomes far more complicated. Many employer plans—perhaps the majority—explicitly exclude coverage for anti-obesity medications, treating them as cosmetic or lifestyle drugs rather than medical necessities. When Wegovy is covered, insurers impose stringent requirements:

• BMI of 30 or higher (or 27+ with weight-related comorbidities like hypertension or sleep apnea)
• Documented failure of at least six months of supervised diet and exercise programs
• Sometimes, proof that you’ve tried older, cheaper weight-loss medications first
• Initial approval for only 3–6 months, with renewal contingent on achieving at least 5% weight loss

A 2024 survey found that coverage varies wildly even among major insurers. Aetna, Cigna, and UnitedHealthcare each have different criteria, tier placements, and quantity limits for these medications.

What to Expect During Prior Authorization

The prior authorization (PA) process can take anywhere from 5–7 business days to several weeks. Your healthcare provider will need to submit detailed documentation including:

• Current BMI calculation and weight history
• List of weight-related health conditions
• Records of previous weight-loss attempts (diet programs, exercise regimens, behavioral counseling)
• Clinical rationale for why this medication is medically necessary

Common reasons for denial include:

• BMI doesn’t meet the threshold
• Insufficient documentation of lifestyle intervention attempts
• Missing comorbidity documentation
• Off-label use (e.g., requesting Ozempic for weight loss when you don’t have diabetes)
• Plan exclusion of all weight-loss medications

If you’re denied, don’t give up. Filing an appeal with additional documentation or a detailed letter of medical necessity from your provider can overturn many denials, especially when the initial rejection was due to incomplete paperwork rather than a hard policy exclusion.

Medicare Coverage: Limited and Diagnosis-Dependent

Traditional Medicare Part D does not cover medications prescribed solely for weight loss—this exclusion is written into federal law. However, there’s an important exception creating a coverage loophole of sorts.

In 2024, Medicare began covering Wegovy for a specific indication: reducing cardiovascular risk in adults with established heart disease and obesity. This means if you have both obesity and diagnosed cardiovascular disease, your Part D plan may cover Wegovy—but not for ‘weight loss’ per se. The coverage is tied to the drug’s FDA approval for preventing heart attacks and strokes.

For diabetes management, Medicare Part D plans do cover Ozempic and Mounjaro, typically placing them in Tier 3 (non-preferred brand) or Tier 4 (specialty tier), resulting in higher copays or coinsurance compared to generic diabetes medications.

Medicare Advantage plans have slightly more flexibility. Some MA plans began offering limited obesity medication coverage in 2025 as an enhanced benefit, but availability varies significantly by plan and region.

Medicaid Coverage: State-by-State Lottery

Medicaid coverage for GLP-1 weight-loss medications represents one of the starkest examples of healthcare inequality in America. Because obesity drugs are considered ‘optional’ benefits under federal Medicaid law, each state decides whether to cover them—and most choose not to.

As of late 2024, only about 13 states provided any Medicaid coverage for medications like Wegovy, and that number is shrinking. Budget pressures are forcing states to roll back coverage even where it existed:

States Cutting or Eliminating Coverage

California: Covered Wegovy through 2025 with strict prior authorization, but coverage ends January 1, 2026 for all adults. The state cited budget constraints, though coverage may continue for children under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Pennsylvania: Initially expanded coverage for GLP-1 weight-loss drugs in 2023, requiring BMI ≥30 or 27+ with comorbidities and documented lifestyle intervention. However, the state announced it will discontinue coverage in January 2026 due to unsustainable costs.

States That Never Covered Weight-Loss Medications

Texas: Explicitly excludes all obesity medications for Medicaid enrollees age 21 and older. Requests for Wegovy, Saxenda, or similar drugs are denied by policy. Children may petition for exceptions through EPSDT.

Florida: Does not include weight-loss drugs on its Medicaid formulary, utilizing the federal optional exclusion. Only diabetes-indicated GLP-1s are covered, and only for Type 2 diabetes treatment.

Illinois: Despite expanding coverage for state employees in 2023, Illinois Medicaid does not cover anti-obesity medications.

States Still Providing Coverage (With Heavy Restrictions)

New York: Covers Wegovy through its NYRx formulary with prior authorization. Requires BMI ≥30 or 27+ with comorbidities, documented lifestyle modification, and regular re-evaluation. Quantity limits of 4 pens per 28 days apply.

Even in states that cover these medications, prior authorization criteria are strict, typically requiring:

• High BMI thresholds
• Documented weight-related comorbidities
• Proof of 6+ months of supervised diet and exercise
• Regular follow-up appointments to demonstrate progress
• Sometimes, trials of cheaper medications first

Cost Without Insurance: New Options in 2025

If your insurance denies coverage or you’re uninsured, you’re not entirely out of options. Recent competitive pressure and manufacturer programs have created new pathways to affordability:

Manufacturer Savings Programs

Novo Nordisk (maker of Wegovy and Ozempic):

• NovoCare Savings Card: For commercially insured patients, can reduce copays to as low as $0 per month (up to $225 monthly savings)
• Wegovy Access Program: Self-pay patients can now get Wegovy for $349/month (down from the previous $499 self-pay price)
• Patient Assistance Program: Provides free medication to qualifying low-income, uninsured patients

Eli Lilly (maker of Mounjaro and Zepbound):

• Savings Card: Reduces Mounjaro copays to $25/month for insured patients with Type 2 diabetes
• LillyDirect: Offers Zepbound (tirzepatide for weight loss) in single-dose vials for $299–$449/month depending on dose
• Patient Assistance: Free medication for qualifying uninsured patients

GoodRx Partnership Program

In November 2025, GoodRx announced a game-changing partnership with Novo Nordisk offering:

• $199/month for the first two fills of Wegovy or Ozempic
• $349/month ongoing pricing at participating pharmacies nationwide
• Additional $39/month telehealth subscription for weight-loss consultations

This represents a 60–70% discount from standard retail prices and has made these medications significantly more accessible to self-pay patients.

Important Caveat: Compounded Versions

You may encounter offers for much cheaper ‘compounded semaglutide’ or ‘compounded tirzepatide’ from online telehealth companies or wellness clinics. While these formulations can cost $200–$300/month, they carry important risks:

• They’re not FDA-approved
• Quality and dosing consistency may vary
• They lack the clinical trial data supporting brand-name versions
• The FDA has issued warnings about compounded GLP-1 products

If cost is prohibitive, manufacturer patient assistance programs or the GoodRx partnership offer safer alternatives at comparable or better prices.

Coverage Comparison: Wegovy, Ozempic, and Mounjaro

Telehealth and Insurance: A Bright Spot

One area where coverage has actually improved is telehealth access. Since the COVID-19 pandemic, most insurers have maintained expanded telehealth coverage, and over 40 states now have telehealth parity laws requiring private insurers to cover virtual visits the same as in-person appointments.

This is particularly relevant for weight-management programs, as many evidence-based approaches include:

• Regular check-ins with a prescribing physician
• Nutritional counseling (often an ACA-mandated preventive service)
• Behavioral health support
• Medication monitoring and adjustment

Key considerations for telehealth and insurance:

• Your provider typically needs to be in-network for coverage to apply
• Most plans cover live video consultations (some restrict phone-only visits)
• Nutritional counseling for obesity is usually a covered preventive benefit
• Some telehealth platforms operate on a cash-pay model even if your eventual prescription is covered by insurance

Platforms like Klarity Health offer virtual consultations with board-certified providers who can evaluate whether GLP-1 medications are appropriate for you, help navigate insurance requirements, and provide prescriptions that can be filled at your regular pharmacy—whether you’re using insurance or paying cash. With provider availability across multiple states and transparent pricing for both insured patients and cash-pay options, telehealth can streamline the process considerably.

What to Do If You’re Denied Coverage

Denial doesn’t have to mean the end of the road. Here’s your action plan:

Step 1: Understand Why You Were Denied

Request a detailed explanation of benefits (EOB) or denial letter. Common reasons include:

• Medical necessity not established
• Insufficient documentation
• Step therapy requirements not met
• Plan exclusion of weight-loss drugs

Step 2: Gather Additional Documentation

Work with your healthcare provider to compile:

• Detailed weight history with dates and BMI calculations
• Comprehensive list of obesity-related health conditions
• Records of supervised diet/exercise programs with dates and outcomes
• Failed attempts with other treatments
• Letter of medical necessity explaining why this medication is appropriate for your specific situation

Step 3: File a Formal Appeal

Most insurers have a two-level internal appeal process:

• First-level appeal: Usually reviewed within 30 days
• Second-level appeal: If first is denied, allows for peer-to-peer review

Be persistent and meet all deadlines. Studies suggest a significant percentage of initial denials are overturned when complete documentation is provided.

Step 4: Consider External Review

If internal appeals fail and you believe the denial is inappropriate, many states allow external independent review of insurance denials, particularly for medically necessary treatments.

Step 5: Explore Alternative Coverage Options

• Check if your employer offers a health spending account (HSA/FSA) that could cover the medication
• Investigate manufacturer patient assistance programs
• Consider the GoodRx partnership pricing
• Look into clinical trials that might provide the medication

The Bottom Line: Coverage Is Complicated, But Options Exist

Insurance coverage for Wegovy, Ozempic, and Mounjaro in 2025 remains frustratingly inconsistent. Whether you’re covered often depends more on your insurance type, geographic location, and diagnosis than on medical need alone.

Key takeaways:

✓ Diabetes medications (Ozempic, Mounjaro) are generally covered with prior authorization, while weight-loss drugs face exclusions or strict criteria

✓ Medicare Part D still won’t cover weight-loss medications except in specific circumstances (CV risk reduction for Wegovy)

✓ Medicaid coverage varies dramatically by state, with many states cutting or never offering coverage due to cost

✓ Prior authorization requirements are nearly universal—be prepared with thorough documentation

✓ Self-pay options have improved significantly, with manufacturer programs and GoodRx partnerships offering 60–70% discounts from list prices

✓ Appeals can work—don’t accept an initial denial without exploring your options

✓ Telehealth coverage is widely available and can make accessing these treatments more convenient

If you’re considering GLP-1 medications for weight management or diabetes, start by checking your specific insurance formulary and speaking with a healthcare provider who can help navigate the prior authorization process. Whether you end up using insurance coverage, manufacturer assistance, or cash-pay options, effective treatment is increasingly within reach—even if it requires persistence and advocacy.

Ready to explore your options? Klarity Health connects you with licensed providers who can evaluate your individual situation, help navigate insurance requirements, and prescribe appropriate medications. With flexible cash-pay and insurance-accepted options, transparent pricing, and providers available across multiple states, getting started with evidence-based weight management or diabetes care is more accessible than ever. Schedule a consultation to discuss whether GLP-1 medications are right for you.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

The information in this article is based on the most current insurance policies, state Medicaid formularies, and pricing programs available as of December 2025. Coverage policies can change with new plan years, state budget cycles, and manufacturer programs. Always verify current coverage with your specific insurance provider and check your plan’s formulary for the latest details.

References

1. Aetna Clinical Policy Bulletin – Weight Loss (BMI ≥35) GIP-GLP-1/GLP-1 Agonists PA with Limit. May 2024. www.aetna.com

2. California Medical Association. ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal.’ December 2025. www.cmadocs.org

3. Texas Children’s Health Plan. ‘Provider Alert: Non-Formulary Requests for Obesity Control Drugs.’ April 28, 2023. www.texaschildrenshealthplan.org

4. Pennsylvania Health Law Project. ‘Pennsylvania Medicaid Covers Newer Weight Loss Drugs.’ August 2024. www.phlp.org

5. GoodRx. ‘GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic and Wegovy.’ BusinessWire, November 17, 2025. www.businesswire.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499